LAKE OSWEGO, Ore., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the launch of a new patient website: www.NeuVax.com. The website will offer patients and investigators information about NeuVax™ (E75 plus GM-CSF) and patient enrollment for the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment) clinical trial. Patients can access the website for treatment information, eligibility criteria, information on the screening process and access other breast cancer advocacy resources. Patients and investigators can also find additional information for the clinical study, including contact information for enrolling sites, at: ClinicalTrials.gov (identifier: NCT01479244).
